Assembly Falls Well Short In Attempt At Finite HBV Therapy
Biotech tried to show that a core inhibitor combined with standard hepatitis B therapy could yield lasting benefit after treatment. Vebicorvir will continue to be studied as a chronic treatment in HBV.
You may also be interested in...
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.